Eli Lilly Stock Price – Live Quote Charts Forecast
Eli Lilly and Company (NYSE: LLY) commands significant attention in the pharmaceutical sector, with shares currently changing hands near $935.58 USD. The Indianapolis-based drugmaker has established itself as a heavyweight in the industry, though recent sessions have shown downward pressure with a 1.98% decline over the past 24 hours according to trading data.
The equity trades with a market capitalization fluctuating between $776 billion and $884 billion, positioning it among the most valuable healthcare companies globally. Investors monitor the stock closely for signals regarding the company’s metabolic disease portfolio and broader pharmaceutical developments.
Understanding the current valuation requires examining not only the headline price but also the broader context of trading volumes, analyst expectations, and technical positioning that has characterized recent market behavior.
What is the Current Eli Lilly Stock Price?
Real-time pricing for LLY reflects continuous order flow on the New York Stock Exchange. The stock currently sits significantly above its 52-week low but has retreated from record highs established in mid-2024.
| Current Price $935.58 USD |
Daily Change -1.98% |
Market Cap $776–884 Billion |
52-Week Range $623.78 – $1,133.95 |
Key Insights on Eli Lilly Valuation
- Mixed momentum signals: Monthly gain of 13.25% contrasts with 12-month decline of 8.36%
- Proximity to historical peaks: Trading roughly 3.8% below the all-time high of $972.53 reached August 22, 2024
- Defensive characteristics: Beta of 0.64 suggests lower volatility than broader market indices
- Valuation spread: P/E ratio ranging from 40.76 to 54.80 indicates variation in trailing earnings calculations
- Income component: Dividend yield between 0.67% and 0.73% provides modest shareholder returns
- Volume contraction: Recent session volume of 2.73 million shares fell below the 3.28 million average
- Market cap variance: $108 billion spread in capitalization estimates reflects real-time trading fluctuations
Comprehensive Financial Snapshot
| Metric | Value |
|---|---|
| Ticker Symbol | LLY |
| Exchange | NYSE |
| Current Price | $935.58 USD |
| Market Capitalization | $776–884 Billion |
| 52-Week High | $1,133.95 |
| 52-Week Low | $623.78 |
| All-Time High | $972.53 (Aug 22, 2024) |
| P/E Ratio (TTM) | 40.76–54.80 |
| Dividend Yield | 0.67–0.73% |
| Revenue (FY) | $45.04 Billion |
| Net Income (FY) | $10.59 Billion |
| Shares Outstanding | 849.83 Million |
How Has Eli Lilly (LLY) Stock Performed Recently?
Recent trading activity reveals a complex picture of volatility and consolidation. The price action across multiple timeframes suggests institutional positioning shifts rather than purely fundamental revaluation.
Recent Session Analysis
During the April 4, 2026 trading session, Eli Lilly opened at $946.61, achieved a daily high of $957.69, and dipped to a low of $930.02 before settling near current levels. Volume reached 2.73 million shares, falling short of the typical 3.28 million average, indicating reduced participation from major institutional accounts.
Multi-Timeframe Returns
Performance varies dramatically depending on measurement windows. The past week delivered a +1.63% gain, while the monthly view shows robust appreciation of +13.25%. However, the 12-month picture presents conflicting data—some sources indicate an 8.36% decline while alternative calculations suggest an 8.23% advance, highlighting the importance of specific measurement dates and dividend reinvestment assumptions.
Historical Context and Ranges
The stock has traveled a wide arc over the past year, bottoming at $623.78 before ascending to within striking distance of the $1,133.95 peak. This $510.17 range demonstrates significant volatility for a large-cap pharmaceutical name, with the current price sitting roughly in the upper third of that band.
12-month performance calculations for LLY show conflicting figures depending on the data provider. Some platforms report an 8.36% decline while others indicate an 8.23% gain. This variance likely stems from different dividend adjustment methods and exact measurement date selection.
Why Is Eli Lilly Stock Price Changing?
Technical analysis reveals specific structural patterns influencing recent price movements. The stock has transitioned from bullish consolidation phases into current downward channel formations.
Technical Pattern Evolution
Earlier in October 2025, analysts identified a bullish flag pattern with theoretical targets exceeding $1,250 if resistance at $972–$973 could be sustained. However, subsequent price action rejected that level, establishing a downward channel characterized by resistance near $772–$780 and support forming around $720–$709.
Critical Support and Resistance Levels
Chart analysis highlights a Genesis Fibonacci level at $635.82 as potential structural support. This level emerged following earnings-related selling pressure and could represent a significant accumulation zone if tested. Immediate resistance remains the $957–$973 band containing recent highs and the all-time peak.
Volume and Liquidity Factors
The contraction in trading volume—evidenced by the April 4 session’s 2.73 million shares versus the 3.28 million average—suggests either consolidation before a directional move or reduced conviction among institutional participants. Volume profiles typically expand during breakout attempts from established channels.
The $635.82 Fibonacci retracement level represents a potential floor based on historical price structure. Traders monitor this zone for potential reversals or acceleration patterns, particularly if accompanied by volume expansion.
What Is the Eli Lilly Stock Forecast and Analyst Outlook?
Wall Street coverage of Eli Lilly spans a wide spectrum of price targets, reflecting uncertainty regarding growth sustainability and competitive positioning in the metabolic drug market.
Analyst Price Targets
Professional analysts currently maintain estimates ranging from a conservative $700.00 to an optimistic $1,190.00, representing a $490 spread. This variance exceeds 50% of the current market price, indicating substantial disagreement regarding the company’s growth trajectory and pipeline valuation.
Macroeconomic Model Projections
Trading Economics utilizes global macro models and analyst expectations to project the stock reaching $851.89 by the end of Q1 2026, with a one-year forecast of $777.50. These figures suggest potential near-term pressure followed by stabilization.
The $490 range between minimum and maximum analyst price targets indicates significant uncertainty regarding Eli Lilly’s future valuation. Investors should note that these projections depend heavily on regulatory outcomes, clinical trial results, and competitive dynamics not fully detailed in current data.
Eli Lilly Stock Price Chronology
- August 22, 2024: Eli Lilly reaches all-time high of $972.53, establishing the current peak valuation benchmark.
- October 17, 2025: Technical analysts identify bullish flag pattern with projected targets above $1,250 contingent on breaking $972–$973 resistance.
- 52-Week Low: Over the past year, the stock touched $623.78, creating the lower bound of the current trading range.
- February 2026: Genesis Fibonacci support level established at $635.82 following earnings-related selling pressure.
- April 4, 2026: Most recent trading session recorded with opening price $946.61, high $957.69, and closing near $935.58.
Established Facts and Information Gaps
| Verified Information | Uncertain or Unavailable Data |
|---|---|
| Current trading price near $935.58 USD with -1.98% daily change | Specific dates for upcoming earnings releases |
| Market capitalization between $776–884 billion | Detailed breakdown of institutional ownership percentages |
| Revenue of $45.04 billion and net income of $10.59 billion | Exact revenue contribution figures for Mounjaro and Zepbound specifically |
| Beta coefficient of 0.64 indicating relative stability | Direct comparative analysis with Novo Nordisk performance metrics |
| Analyst price target range of $700–$1,190 | Detailed dividend payment schedules and ex-dividend dates |
| Technical support levels at $635.82 and $720–$709 | FDA approval timelines for pipeline candidates |
Eli Lilly Stock Fundamentals and Ownership
The company trades at a premium valuation with trailing P/E ratios between 40.76 and 54.80, reflecting investor expectations for continued growth in metabolic and oncology therapies. Basic earnings per share stand at $15.11, supporting the current price structure despite the elevated multiple.
With 849.83 million shares outstanding, the float remains sufficiently liquid for institutional trading, though the beta of 0.64 suggests the stock moves with less volatility than the broader market. The dividend yield of 0.67–0.73% provides nominal income, though growth investors typically prioritize capital appreciation over yield in this equity.
Comprehensive data regarding specific institutional holders and competitive positioning against rivals like Novo Nordisk remains unavailable in current disclosures. For those managing Canadian currency exposure alongside U.S. equities, converting amounts like 20000 CAD to INR requires monitoring similar exchange rate volatility factors.
Market Data Sources and Technical Commentary
Market data derives from verified exchange feeds and analytical platforms. TradingView provides technical pattern recognition including the bullish flag and downward channel formations. Robinhood data confirms recent session specifics including the April 4, 2026 trading statistics.
“The stock previously formed a bullish flag pattern with a potential target above $1,250 if resistance at $972–973 was crossed and sustained. Current price action shows the stock trading in a downward channel with resistance near $772–780.”
Technical Analysis Summary, TradingView
“A Genesis Fibonacci level at $635.82 was identified as a potential support area following earnings-related selling pressure.”
Chart Analysis, TradingView
Additional fundamental data is available through the SEC EDGAR database and Eli Lilly Investor Relations portal. Real-time quotes appear on Nasdaq and Yahoo Finance platforms.
Investment Snapshot
Eli Lilly currently trades at $935.58, down 1.98% in recent sessions, with a market cap approaching $884 billion at the upper estimate. The stock maintains a wide analyst target range of $700–$1,190 while exhibiting technical characteristics of a downward channel with support near $720. Investors weighing pharmaceutical exposure should consider the 0.64 beta coefficient and 0.73% dividend yield alongside growth projections. Those accessing investment accounts through Canadian financial institutions may reference the Northern Credit Union Login portal for portfolio management tools.
Frequently Asked Questions
What is Eli Lilly’s current dividend yield?
Eli Lilly offers a dividend yield ranging between 0.67% and 0.73%, representing modest income relative to the stock price.
How does Eli Lilly’s volatility compare to the overall market?
With a beta coefficient of 0.64, Eli Lilly exhibits lower volatility than the broader market, suggesting the stock moves approximately 64% as much as market indices.
What is the 52-week trading range for LLY?
The stock has traded between a low of $623.78 and a high of $1,133.95 over the past 52 weeks.
When did Eli Lilly reach its all-time high price?
The stock achieved its all-time high of $972.53 on August 22, 2024.
What are Wall Street analysts’ price targets for Eli Lilly?
Analysts maintain a wide range of price targets from $700.00 at the low end to $1,190.00 at the high end.
More related posts
Jobs Near Me Hiring Immediately – 2025 Guide to Quick Hires
Chad Michael Murray: Bio, Health Scare, Family & Career
Biggie Smalls: Life, Murder, and Unsolved Case
Canada Day 2025 in Quebec: Dates, Closures, Celebrations
William H. Macy Biography: Age, Movies, Net Worth & Family
Natasha Romanoff: Age, Death, Sexualization & Weakest Avenger
Barberian’s Steak House Menu: Toronto Prices & Items
Saudi Pro League Stats – 2024/25 Standings Top Scorers Records
